SI2014652T1 - Aktivacijsko sredstvo za peroksisomski proliferatorski aktivirani receptor - Google Patents

Aktivacijsko sredstvo za peroksisomski proliferatorski aktivirani receptor

Info

Publication number
SI2014652T1
SI2014652T1 SI200731540T SI200731540T SI2014652T1 SI 2014652 T1 SI2014652 T1 SI 2014652T1 SI 200731540 T SI200731540 T SI 200731540T SI 200731540 T SI200731540 T SI 200731540T SI 2014652 T1 SI2014652 T1 SI 2014652T1
Authority
SI
Slovenia
Prior art keywords
activating agent
activated receptor
peroxisome proliferator
proliferator activated
peroxisome
Prior art date
Application number
SI200731540T
Other languages
English (en)
Inventor
Shogo Sakuma
Nobutaka Mochiduki
Masatoshi Ushioda
Rie Takahashi
Tomio Yamakawa
Seiichiro Masui
Original Assignee
Nippon Chemiphar Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co., Ltd. filed Critical Nippon Chemiphar Co., Ltd.
Publication of SI2014652T1 publication Critical patent/SI2014652T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
SI200731540T 2006-04-18 2007-04-18 Aktivacijsko sredstvo za peroksisomski proliferatorski aktivirani receptor SI2014652T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006114561 2006-04-18
EP07742334.1A EP2014652B1 (en) 2006-04-18 2007-04-18 Activating agent for peroxisome proliferator activated receptor
PCT/JP2007/058899 WO2007119887A1 (ja) 2006-04-18 2007-04-18 ペルオキシソーム増殖剤活性化受容体δの活性化剤

Publications (1)

Publication Number Publication Date
SI2014652T1 true SI2014652T1 (sl) 2014-12-31

Family

ID=38609637

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731540T SI2014652T1 (sl) 2006-04-18 2007-04-18 Aktivacijsko sredstvo za peroksisomski proliferatorski aktivirani receptor

Country Status (23)

Country Link
US (2) US8404726B2 (sl)
EP (1) EP2014652B1 (sl)
JP (3) JP5290749B2 (sl)
KR (1) KR101507173B1 (sl)
CN (2) CN101466687B (sl)
AU (1) AU2007239283B2 (sl)
BR (1) BRPI0710266B8 (sl)
CA (1) CA2649735C (sl)
CY (1) CY1115637T1 (sl)
DK (1) DK2014652T3 (sl)
ES (1) ES2522291T3 (sl)
HK (1) HK1135377A1 (sl)
IL (1) IL194847A (sl)
MX (1) MX2008013292A (sl)
MY (1) MY154836A (sl)
NO (1) NO341476B1 (sl)
NZ (1) NZ572268A (sl)
PL (1) PL2014652T3 (sl)
PT (1) PT2014652E (sl)
RU (1) RU2435764C2 (sl)
SI (1) SI2014652T1 (sl)
WO (1) WO2007119887A1 (sl)
ZA (1) ZA200809148B (sl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2014652T1 (sl) 2006-04-18 2014-12-31 Nippon Chemiphar Co., Ltd. Aktivacijsko sredstvo za peroksisomski proliferatorski aktivirani receptor
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN102083810B (zh) 2008-04-15 2014-10-29 日本化学医药株式会社 过氧化物酶体增殖剂活化受体的活化剂
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN103002742B (zh) * 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2012207565B2 (en) 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US9428490B2 (en) 2011-07-29 2016-08-30 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
KR20210083380A (ko) 2011-07-29 2021-07-06 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2014DN09434A (sl) 2012-05-09 2015-07-17 Karyopharm Therapeutics Inc
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
WO2014165827A1 (en) 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
ES2952774T3 (es) 2013-06-21 2023-11-06 Karyopharm Therapeutics Inc 1,2,4-triazoles como moduladores del transporte nuclear y uso en el tratamiento de formas específicas de cáncer
GB2534052A (en) * 2013-08-30 2016-07-13 Council Scient Ind Res Pyrazolochalcones as potential anticancer agents
JP6777626B2 (ja) 2014-08-15 2020-10-28 カリオファーム セラピューティクス，インコーポレイテッド セリネクソールの多形体
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
CA2991161A1 (en) * 2015-07-02 2017-01-05 The Medical College Of Wisconsin, Inc. Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors
EP3770146A1 (en) 2015-10-07 2021-01-27 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
KR102430906B1 (ko) 2016-04-13 2022-08-10 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
EP3705120A4 (en) * 2017-11-15 2021-08-11 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR RECEPTOR ACTIVATED BY PEROXISOMPROLIFERATOR

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956379A (en) 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
GB9426448D0 (en) 1994-12-30 1995-03-01 Wellcome Found Process
AU714054B2 (en) 1995-01-06 1999-12-16 Toray Industries, Inc. Benzene-fused heterocyclic derivatives and use of the same
CA2171702A1 (en) 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
AU5121796A (en) 1995-05-08 1996-11-29 Nippon Chemiphar Co. Ltd. 2,4-thiazolidinedione or oxazolidinedione derivatives and hy poglycemic agent
ATE216384T1 (de) 1996-01-22 2002-05-15 Fujisawa Pharmaceutical Co Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten
ATE245622T1 (de) 1996-02-02 2003-08-15 Merck & Co Inc Antidiabetische mittel
US20020032330A1 (en) 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
JP4427825B2 (ja) 1997-07-24 2010-03-10 アステラス製薬株式会社 コレステロール低下作用を有する医薬組成物
US6589969B1 (en) 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1206457B1 (en) 1999-08-27 2003-10-15 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
JP2001261674A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
ATE542805T1 (de) 2000-08-11 2012-02-15 Nippon Chemiphar Co Ppar-delta aktivatoren
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1368011A1 (en) 2001-02-22 2003-12-10 SmithKline Beecham Corporation Method for treating ppar gamma mediated diseases
US7078422B2 (en) 2001-03-23 2006-07-18 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
AU2002323776B2 (en) * 2001-08-10 2008-07-31 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor Delta
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
DE60210784T2 (de) 2001-08-29 2006-11-02 Warner-Lambert Co. Llc Orale antidiabetische wirkstoffe
DE60232739D1 (de) 2001-10-12 2009-08-06 Nippon Chemiphar Co Aktivator des peroxisomproliferator-aktivierten rezeptors delta
JP2003292439A (ja) 2002-02-04 2003-10-15 Sumitomo Pharmaceut Co Ltd 新規ピロール誘導体からなるｐｐａｒ活性化剤
ES2290439T3 (es) * 2002-02-25 2008-02-16 Eli Lilly And Company Moduladores del receptor activado del proliferador de peroxisomas.
CA2487315A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
JPWO2004007439A1 (ja) 2002-07-10 2005-11-10 住友製薬株式会社 ビアリール誘導体
US6800655B2 (en) 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
WO2004022551A1 (ja) 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited フランまたはチオフェン誘導体およびその医薬用途
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
EP1583746A1 (en) 2003-01-06 2005-10-12 Eli Lilly And Company A pyrazole derivative as ppar modulator
EP1583754A1 (en) 2003-01-06 2005-10-12 Eli Lilly And Company Thiophene derivative ppar modulators
AU2003300131A1 (en) 2003-01-06 2004-11-04 Eli Lilly And Company Indole derivatives as ppar modulators
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
US20070054902A1 (en) 2003-12-02 2007-03-08 Shionogi & Co., Ltd. Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
GB0403148D0 (en) 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
FR2869611B1 (fr) 2004-05-03 2006-07-28 Merck Sante Soc Par Actions Si Derives de l'acide hexenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
JP2008500358A (ja) 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法
CA2609980C (en) 2005-05-27 2015-10-13 Queen's University At Kingston Treatment of protein folding disorders
EP1916247A4 (en) 2005-07-06 2009-07-15 Nippon Chemiphar Co PEROXYSOME PROLIFERATOR ACTIVATED RECEPTOR ACTIVATOR
SI2014652T1 (sl) 2006-04-18 2014-12-31 Nippon Chemiphar Co., Ltd. Aktivacijsko sredstvo za peroksisomski proliferatorski aktivirani receptor
WO2008016175A1 (fr) 2006-08-03 2008-02-07 Nippon Chemiphar Co., Ltd. Agent activant de récepteur activé par les proliférateurs des peroxysomes

Also Published As

Publication number Publication date
MX2008013292A (es) 2008-11-14
ZA200809148B (en) 2010-01-27
HK1135377A1 (en) 2010-06-04
KR101507173B1 (ko) 2015-03-30
CY1115637T1 (el) 2017-01-04
US8404726B2 (en) 2013-03-26
MY154836A (en) 2015-07-31
CA2649735C (en) 2016-02-09
PL2014652T3 (pl) 2015-02-27
EP2014652A4 (en) 2010-10-06
WO2007119887A1 (ja) 2007-10-25
CN102643248A (zh) 2012-08-22
AU2007239283A1 (en) 2007-10-25
RU2008145505A (ru) 2010-05-27
AU2007239283B2 (en) 2013-02-07
RU2435764C2 (ru) 2011-12-10
NO20084856L (no) 2008-12-29
KR20090006853A (ko) 2009-01-15
JP6049791B2 (ja) 2016-12-21
NO341476B1 (no) 2017-11-27
CN101466687A (zh) 2009-06-24
JP5782016B2 (ja) 2015-09-24
EP2014652A1 (en) 2009-01-14
JP2015163611A (ja) 2015-09-10
EP2014652B1 (en) 2014-08-06
BRPI0710266A2 (pt) 2012-02-28
US20130217734A1 (en) 2013-08-22
US20090298896A1 (en) 2009-12-03
JP5290749B2 (ja) 2013-09-18
CN101466687B (zh) 2012-04-11
NZ572268A (en) 2011-09-30
BRPI0710266B1 (pt) 2020-07-14
JP2013067652A (ja) 2013-04-18
IL194847A0 (en) 2009-08-03
CA2649735A1 (en) 2007-10-25
JPWO2007119887A1 (ja) 2009-08-27
PT2014652E (pt) 2014-11-12
ES2522291T3 (es) 2014-11-14
IL194847A (en) 2013-10-31
DK2014652T3 (da) 2014-10-13
BRPI0710266B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HK1135377A1 (en) Activating agent for peroxisome proliferator activated receptor
HRP20181168T1 (hr) Aktivator za receptore koji se aktiviraju peroksisom proliferatorom
ZA200808530B (en) Pharmaceutical composition for external use
ZA200808531B (en) Pharmaceutical composition for external use
IL224109A (en) Isoxazole derivatives for use as fungicides
GB2442198B (en) Toilet Device
EP2091476A4 (en) DEVICE FOR PREVENTING SNORES
IL194368A0 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
EP2123224A4 (en) ULTRASOUND DEVICE
IL197093A0 (en) Pharmaceutical composition comprising candesartan cilexetil
EP2000096A4 (en) ULTRASONIC IMAGING DEVICE
EP2030573A4 (en) ULTRASOUND DEVICE
EP2001833A4 (en) ANTIDIABETIC CATARACT COMPOUNDS AND THEIR APPLICATION
EP2066640A4 (en) 2- (1-OXO-1H-ISOCHINOLIN-2-YL) ACETAMIDE DERIVATIVES
EP2070876A4 (en) FLUID ACTIVATION DEVICE
IL188616A0 (en) Activator of peroxisome proliferator activated receptor ??
IL185536A0 (en) Activator for peroxisome proliferator activating receptor delta
IL187530A0 (en) Activator for peroxisome proliferator-activated receptor
EP2062534A4 (en) ULTRASONIC DEVICE
EP2067480A4 (en) MUSCLIN RECEPTOR AND USE THEREOF
GB0608960D0 (en) Imaging agent
EP2039359A4 (en) ANALGICAL AGENT
HU0600014D0 (en) Hydraulic device
GB0707507D0 (en) A sanitary composition
GB0603803D0 (en) Improved sanitary pad